Remove Drug Research Remove Drugs Remove Therapies
article thumbnail

Startup Mariana raises $175M for radiopharmaceutical drug research

BioPharma Drive: Drug Pricing

The Series B round makes Mariana one of the best funded private companies in a growing group of biotechs working on new radiopharmaceutical therapies.

article thumbnail

Sarepta sells FDA fast pass earned from Duchenne gene therapy approval

BioPharma Drive: Drug Pricing

The deal enables Sarepta to quickly cash in on the clearance of Elevidys, with $102 million in new funds to help bankroll its drug research.

Therapies 110
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease

BioPharma Drive: Drug Pricing

Allogene’s partnership with Arbor is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.

article thumbnail

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

The road to developing effective drugs is fraught with both promise and challenge, particularly when it comes to what scientists call "undruggable" targets. The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess.

article thumbnail

eBook: Unlocking Undruggable Targets

DrugBank

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy.

article thumbnail

AI in gene delivery vector discovery and design

Drug Target Review

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. Consequently, an increasing number of academic researchers and companies are entering this field.

article thumbnail

In vivo preclinical models for immune-mediated inflammatory disease drug development

Crown Bioscience

Interest in IMIDs has grown rapidly in recent years, largely fueled by the view that IMIDs share common inflammatory pathways, and therefore, there is the possibility that novel therapies that work in one IMID may work in other IMIDs.

Disease 52